A new study conducted in one county in Minnesota has found an increased likelihood that citizens who received the Johnson & Johnson’s COVID-19 vaccine were more likely to develop blood clots.
The study by the Mayo Clinic found that recipients of the Johnson & Johnson vaccine, officially designated “Janssen,” in Olmsted County, Minnesota, were about 3.7 times more likely to develop a certain variety of cerebral blood clots. Case numbers taken from February 28 to May 7, 2021, were compared to pre-pandemic levels of the blood clots from January 1, 2001, through December 31, 2015.
In this population-based cohort study, we found that the CVST incidence rate 15 days after Ad26.COV2.S vaccination was significantly higher than the prepandemic rate. However, the higher rate of this rare adverse effect must be considered in the context of the effectiveness of the vaccine in preventing COVID-19 (absolute reduction of severe or critical COVID-19 of 940 per 100 000 PY).
Cleveland Clinic CEO and Mayo Clinic President say the response to COVID-19 could be as big a disaster as the virus itself.
“The true cost of this epidemic will not be measured in dollars; it will be measured in human lives and human suffering. In the case of cancer alone, our calculations show we can expect a quarter of a million additional preventable deaths annually if normal care does not resume,” they wrote.